Anup Kundu Email & Phone Number | Kundu lab at Xavier University of Louisiana works in the highly interdisciplinary areas of nanoparticle formulation, characterization and targeted delivery of drugs and genes into breast cancer cells. The development of multidrug resistance (MDR) in cancer cells is of grave concern, limiting the efficacy of anticancer agents and, hence, the failure of breast cancer therapy. Clinical research and application revealed that in spite of it’s potential anticancer effects, doxorubicin is highly toxic, and its long-term application may cause dose-dependent irreversible cardiomyopathy, severe cardiac toxicity, or liver damage, thereby limiting its application in breast cancer treatment. As such, the greater potential of using doxorubicin as anticancer therapeutic depends on the availability of a targeted delivery vehicle, which will not only enhance the killing of cancer cells but also minimize the off-target toxicity to non-cancerous cells. The goal of Kundu lab at Xavier University of Louisiana is to enhance the delivery of doxorubicin by formulating an aptamer-labeled liposomal nanoparticle delivery system that will carry and deliver doxorubicin specifically into chemoresistant breast cancer cells.

Anup Kundu

Kundu lab at Xavier University of Louisiana works in the highly interdisciplinary areas of nanoparti...
Kenner, Louisiana, United States

*50 free lookup(s) per month.

Anup Kundu’s Email akundu@xula.edu

Anup Kundu’s Phone Numbers

Get ANUP’s Phone Number (For Free)

Social Media

Anup Kundu’s Location Kenner, Louisiana, United States

Anup Kundu’s Current Industry Xavier University Of Louisiana

Anup Kundu’s Prior Industry

Find accurate emails & phone numbers for over 700M professionals.

Associate Professor

2018-08-01 00:00:00 - Present

No Skills Available

No Languages Available

Anup Kundu is a Kundu lab at Xavier University of Louisiana works in the highly interdisciplinary areas of nanoparticle formulation, characterization and targeted delivery of drugs and genes into breast cancer cells. The development of multidrug resistance (MDR) in cancer cells is of grave concern, limiting the efficacy of anticancer agents and, hence, the failure of breast cancer therapy. Clinical research and application revealed that in spite of it’s potential anticancer effects, doxorubicin is highly toxic, and its long-term application may cause dose-dependent irreversible cardiomyopathy, severe cardiac toxicity, or liver damage, thereby limiting its application in breast cancer treatment. As such, the greater potential of using doxorubicin as anticancer therapeutic depends on the availability of a targeted delivery vehicle, which will not only enhance the killing of cancer cells but also minimize the off-target toxicity to non-cancerous cells. The goal of Kundu lab at Xavier University of Louisiana is to enhance the delivery of doxorubicin by formulating an aptamer-labeled liposomal nanoparticle delivery system that will carry and deliver doxorubicin specifically into chemoresistant breast cancer cells.